From €6267EUR$6,500USD£5,360GBP
- Report
- February 2024
- 150 Pages
Global
From €4579EUR$4,750USD£3,917GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4579EUR$4,750USD£3,917GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4579EUR$4,750USD£3,917GBP
- Report
- February 2024
- 80 Pages
Europe
From €4579EUR$4,750USD£3,917GBP
- Report
- February 2024
- 181 Pages
Europe
From €4579EUR$4,750USD£3,917GBP
- Report
- February 2024
- 70 Pages
United States
From €4579EUR$4,750USD£3,917GBP
- Report
- August 2023
- 70 Pages
Middle East, Africa
From €4579EUR$4,750USD£3,917GBP
- Report
- August 2023
- 150 Pages
North America
From €4579EUR$4,750USD£3,917GBP
- Report
- February 2021
- 500 Pages
United States
From €2314EUR$2,400USD£1,979GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4579EUR$4,750USD£3,917GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4579EUR$4,750USD£3,917GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4579EUR$4,750USD£3,917GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4579EUR$4,750USD£3,917GBP
- Report
- February 2024
- 70 Pages
India
From €4579EUR$4,750USD£3,917GBP
- Report
- February 2024
- 70 Pages
Germany
From €4579EUR$4,750USD£3,917GBP
- Report
- February 2024
- 70 Pages
Italy
From €4579EUR$4,750USD£3,917GBP
- Report
- February 2024
- 70 Pages
Oman
From €4579EUR$4,750USD£3,917GBP
- Report
- February 2024
- 70 Pages
Egypt
From €4579EUR$4,750USD£3,917GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4579EUR$4,750USD£3,917GBP
Bydureon is a medication used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as Endocrine and Metabolic Disorders Drugs. Bydureon is a long-acting form of exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by stimulating the release of insulin from the pancreas and decreasing the amount of glucose produced by the liver. It also helps to reduce appetite and slow the absorption of glucose from the intestines.
Bydureon is available in the form of an injection and is typically taken once a week. It is usually prescribed in combination with other diabetes medications, such as metformin, sulfonylureas, and thiazolidinediones.
The Bydureon market includes companies such as AstraZeneca, Eli Lilly, Novo Nordisk, and Sanofi. These companies are involved in the research, development, and marketing of Bydureon and other Endocrine and Metabolic Disorders Drugs. Show Less Read more